Indexed metadata
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
Iain B McInnes, Joachim Sieper, Jürgen Braun, Paul Emery, Désirée van der Heijde, John D Isaacs, Georg Dahmen, Jürgen Wollenhaupt, Hendrik Schulze-Koops, Joseph Kogan, Shenglin Ma, Martin M Schumacher, Arthur P Bertolino, Wolfgang Hueber, Paul P Tak
Source record
Source: Crossref
Published: Feb 1, 2014
DOI: 10.1136/annrheumdis-2012-202646
Open original source ↗Evidence graph
No public relationships recorded yet.
Integrity note: This page is a factual metadata record created by deterministic ingestion. It is not a claim that the work moves a mathematical frontier or has been independently verified.